CSL Ltd. — Board/Management Information 2008

Sep 1, 2008

For immediate release 2 September, 2008

==> picture [205 x 32] intentionally omitted <==

==> picture [59 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

CSL APPOINTS NEW DIRECTOR

CSL today announced that Mr David Anstice has been appointed a Director of the Company effective from 2 September 2008.

Mr Anstice was a senior executive of Merck & Co, Inc, for many years, retiring as of 1 September 2008. Mr Anstice served as President of Merck Human Health for the US/Canada, Europe, Japan and Asia, in separate assignments. He has also been responsible for Merck’s prescription drug business in Latin America, Australia and New Zealand, and its joint venture relationship with Schering Plough.

Mr Anstice was a longtime member of the Board of Directors and Executive Committee of the U.S. Biotechnology Industry Organisation, and is Chairman and President of the University of Sydney USA Foundation. Mr Anstice is an Adjunct Professor in the Faculty of Economics and Business at Sydney University and holds a Bachelor of Economics from that University which he obtained in 1970. Mr Anstice will continue to reside in the US.

CSL’s Chairman, Miss Elizabeth Alexander, said that she was delighted that David Anstice had accepted the appointment to the CSL Board, noting that she was sure that with David’s wealth of professional experience in the pharmaceutical industry and in International Business and Economics, he was very well placed to provide CSL with great insight into industry issues.

For more information about CSL Limited, visit www.csl.com.au

Media Contacts

Dr Rachel David Director of Public Affairs Phone: 0401 775 779

Investor Contact:

Mark Dehring Director of Investor Relations Phone: 61 3 9389 2818 Email: mark.dehring@csl.com.au

==> picture [98 x 7] intentionally omitted <==